Skip to content

Safety Observation of Xueshuantong Injection (lyophilized) Real-world Retrospective Study

Safety Observation of Xueshuantong Injection (lyophilized) Real-world Retrospective Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049331
Enrollment
Unknown
Registered
2021-07-30
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Approved Indications of Xueshuantong Injection (lyophilized)

Interventions

Case series:Use of Xueshuantong for injection (lyophilized)

Sponsors

Yixing People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Meet the basis for western medicine diagnosis or TCM syndrome diagnosis standard, and the specific requirements are as follows: 1.There is a basis for western medicine diagnosis - according to the disease diagnosis code or diagnosis name during hospitalization or outpatient, combined with other treatment of patients for comprehensive analysis. 2.Meet the basis for TCM syndrome diagnosis standard - refer to the Classification and Code of TCM Syndrome and the Terms of TCM Clinical Diagnosis and Treatment, and comprehensively analyze the other treatment conditions of patients.

Exclusion criteria

Exclusion criteria: 1.Known to be allergic to Xueshuantong injection (lyophilized); 2.Known to be allergic to ginseng and notoginseng; 3.Patients in the acute phase of bleeding disorders; 4.Children.

Design outcomes

Primary

MeasureTime frame
Clinical symptoms;Safety information;

Secondary

MeasureTime frame
Occurrence of adverse events;Medication Rationality Information;

Countries

China

Contacts

Public ContactXu Yunfei

Yixing People's Hospital

staff1757@yxph.com+86 15301539918

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026